S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Biogen Inc.

BIIB · Healthcare · · USD
220.83 USD
0.00 (-1.64%)
● Updated 2026-09-07 20:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Mid-term (Position)

79
/ 100
Technical 100
Trend & RS 90
Momentum 72
Fundamental 67
Macro 64
Liquidity 38
ComponentScoreWeight
Technical 100.0 20%
Trend & RS 89.9 30%
Momentum 71.6 15%
Fundamental 66.7 10%
Macro 64.4 20%
Liquidity 37.8 5%

Trade Setup

Entry 220.83
Stop Loss 209.07 (5.3%)
Target 1 (1:1) 232.59 (+5.3%)
Target 2 (2:1) 244.35 (+10.7%)
ATR(14) 5.88 (2.7%)
Risk per Share 11.76
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 55.5 +0.22
Momentum 71.6 +0.87
Quality 34.9 -0.60
Composite 54.0

Quality Scores

Piotroski F-Score 6 /9 — Average
✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✗
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Fair Value

MetricStockSectorvs Peers
P/E Ratio 39.2 22.0 +78% above
P/B Ratio 1.7 4.0 Below

Comparing against Healthcare median multiples.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
73.84
vs
Market Price
220.83
Upside
-66.6%
Margin of Safety -199.1%
Stage 1 PV (5yr FCF)2,848,375,027
Terminal Value PV8,061,546,357
Total Enterprise Value10,909,921,384

Assumptions

Base FCF665,484,037
Growth Rate (5yr)3.4%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
51.01%
Full Kelly
25.5%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 79/100. Estimated win rate 64%, avg win 9.7%, avg loss 3.4%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

4
Bullish Signals
0
Bearish Signals
57.98
RSI(14)
4.0396
MACD

Relative Strength (RS) IMPROVING

74
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↑ RISING (+8.3% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (49d since high)
Sector Outperformance +5.3% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 57.98 NEUTRAL
Macd 4.0396 BULLISH
Ma Cross 209.53 / 191.05 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.65x NORMAL

Key Levels

LevelPrice
52-Week High225.80
Bollinger Upper227.6
SMA(200)191.05
SMA(50)209.53
SMA(20)215.77
Current Price220.83
Bollinger Lower203.94
52-Week Low135.39
ATR(14)5.88

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.16x Normal bar — no special VSA pattern
2026-09-01 Normal 1.1x Normal bar — no special VSA pattern
2026-09-02 Normal 1.78x Normal bar — no special VSA pattern
2026-09-03 Normal 0.77x Normal bar — no special VSA pattern
2026-09-04 Normal 0.65x Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 219.69 Above Kijun
Kijun-sen (26) 212.69 Base line
Senkou A 216.19 Leading span A
Senkou B 205.92 Leading span B
Cloud 205.92 – 216.19 Bullish (Green)
Price vs Cloud 220.83 Above Cloud
Chikou Span 202.95 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 203.94 – 227.6  |  KC: 207.73 – 223.82

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bullish MACD 4
Regular Bearish RSI 28

Anchored VWAP

VWAP: 180.99 Anchor: 2025-09-29 (52w Low) ABOVE AVWAP +22.0%

Heikin-Ashi Trend

EXHAUSTION Trend exhaustion (3 doji candles) Full data via /api/advanced/BIIB

Valuation

MetricValue
Market Cap32.63B
P/E (TTM)39.22
Forward P/EN/A
P/B1.73
EPS5.63

Financial Health

MetricValue
Revenue Growth3.4%
Profit Margin8.3%
ROE4.6%
Debt/Equity44.33
Current Ratio1.86
Dividend YieldN/A
Payout RatioN/A
Beta0.17

Trading Data

220.83
Open
220.83
Day High
220.83
Day Low
465.1K
Volume (0.4x avg)

Recent News (8)

This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Barrons.com · 2026-09-04
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Zacks · 2026-09-04
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Simply Wall St. · 2026-09-04
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Simply Wall St. · 2026-09-03
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
Simply Wall St. · 2026-09-03
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Zacks · 2026-09-02
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
Insider Monkey · 2026-09-02
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
Insider Monkey · 2026-08-30

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —